Clinical trial

Ketamine Challenge Study With JNJ-40411813

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedPhase 1Started Feb 1, 201040 enrolledGermanyNCT01101659

Abstract

The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine. Effects of JNJ-40411813 on ketamine-induced symptoms will be evaluated about 3 hours after a single oral dose when the concentration of JNJ-40411813 in the blood is at its maximum and up to 24 hours after dose administration to assess the duration of a potential JNJ-40411813 effect.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Ketamine

Keywords

Activity of JNJ-40411813Challenge studyPerceptual DisordersConfusionSchizophrenia

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleMDMA

Chemsex drugs: More than ghb, mephedrone and methamphetamine?

Ramos J, Dolengevich H, Romerosa M +1

Europe PMC2021

ArticleKetamine

Midazolam-Ketamine (MK) Versus Propofol-Ketamine (PK) for Pediatric Burn Patients Undergoing Dressing Changes: A Non-Randomized Cross-Over Clinical Trial.

Guellim S, Hamada HB, Bouji N +4

Europe PMC2025

ArticleKetamine

Efficacy and safety comparison of esketamine-propofol with nalbuphine-propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial.

Zheng X, Huang J, Wei S +6

Europe PMC2023